Scholarlink

Abstract <p>Colistin has served as a last-resort agent against multidrug-resistant Gram-negative bacilli (MDR-GNB). However, the emergence of resistance has substantially eroded its therapeutic value, particularly among hospitalized patients. Evidence regarding the clinical outcomes of colistin-resistant infections in Saudi Arabia, however, remains scarce. This study aimed at assessing the clinical characteristics and outcomes of colistin-resistant bacterial infections among hospitalized patients in the Qassim region.&#xa0;We conducted a single-center retrospective observational study at King Fahad Specialist Hospital, Qassim, Saudi Arabia, reviewing the records of hospitalized patients with colistin-resistant infections between 2019 to 2023. Demographic, clinical, microbiological, therapeutic, and outcome data were retrieved from both electronic and paper health records.&#xa0;Eighty-five patients (mean age, 65.8&#xa0;years; 60% male) with eighty-five colistin-resistant isolates were identified. Enterobacterales predominated (85.9%), followed by <i>Pseudomonas aeruginosa</i> (9.4%) and <i>Acinetobacter baumannii</i> (4.7%). All isolates showed extensive colistin resistance (100% in <i>Acinetobacter</i> and <i>Pseudomonas</i>, 82.8% in <i>Enterobacterales</i>), acknowledging the small number of non-Enterobacterales isolates. Limited sensitivity to cephalosporins and carbapenems, underscoring the therapeutic challenge of MDR-GNB. Meropenem (39.7%) and tigecycline (15.1%) were the most frequently prescribed agents, whereas combination therapy was employed in 16.6% of cases. The overall in-hospital mortality was 54.1% (95% CI: 43.0–65.0), with substantially higher mortality among patients admitted to the ICU (70.8%, 95% CI: 55.9–83.0) compared with those managed in non-ICU settings (32.4%, 95% CI: 18.0–49.8). After adjustment for clinical indicators, ICU admission was independently associated with increased mortality.&#xa0;Colistin-resistant Gram-negative infections hospitalized patients were characterized by severely limited therapeutic options, substantial reliance on carbapenems and tigecycline, and high observed mortality. These observations underscore the need for strengthened antimicrobial stewardship, improved availability of rapid diagnostic tools, and expanded access to newer therapeutic agents. In the absence of such measures, the burden of colistin resistance is likely to persist in hospital settings, including patients requiring intensive care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comorbidities and mortality in colistin-resistant gram-negative infections among hospitalized patients in Qassim, Saudi Arabia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月27日

查看全文
  • Masaad Saeed Almutairi,
  • Mohammed Albulaihed,
  • Faisal Almutairi,
  • Yasser Alsuhaibani,
  • Mohammed Alkathlan,
  • Faris S. Alnezary,
  • Abdulrahman Saleh Aljamhan,
  • Afaf Ibrahim Alresheedi,
  • Zikria Saleem,
  • Omar A. Almohammed

摘要

Abstract

Colistin has served as a last-resort agent against multidrug-resistant Gram-negative bacilli (MDR-GNB). However, the emergence of resistance has substantially eroded its therapeutic value, particularly among hospitalized patients. Evidence regarding the clinical outcomes of colistin-resistant infections in Saudi Arabia, however, remains scarce. This study aimed at assessing the clinical characteristics and outcomes of colistin-resistant bacterial infections among hospitalized patients in the Qassim region. We conducted a single-center retrospective observational study at King Fahad Specialist Hospital, Qassim, Saudi Arabia, reviewing the records of hospitalized patients with colistin-resistant infections between 2019 to 2023. Demographic, clinical, microbiological, therapeutic, and outcome data were retrieved from both electronic and paper health records. Eighty-five patients (mean age, 65.8 years; 60% male) with eighty-five colistin-resistant isolates were identified. Enterobacterales predominated (85.9%), followed by Pseudomonas aeruginosa (9.4%) and Acinetobacter baumannii (4.7%). All isolates showed extensive colistin resistance (100% in Acinetobacter and Pseudomonas, 82.8% in Enterobacterales), acknowledging the small number of non-Enterobacterales isolates. Limited sensitivity to cephalosporins and carbapenems, underscoring the therapeutic challenge of MDR-GNB. Meropenem (39.7%) and tigecycline (15.1%) were the most frequently prescribed agents, whereas combination therapy was employed in 16.6% of cases. The overall in-hospital mortality was 54.1% (95% CI: 43.0–65.0), with substantially higher mortality among patients admitted to the ICU (70.8%, 95% CI: 55.9–83.0) compared with those managed in non-ICU settings (32.4%, 95% CI: 18.0–49.8). After adjustment for clinical indicators, ICU admission was independently associated with increased mortality. Colistin-resistant Gram-negative infections hospitalized patients were characterized by severely limited therapeutic options, substantial reliance on carbapenems and tigecycline, and high observed mortality. These observations underscore the need for strengthened antimicrobial stewardship, improved availability of rapid diagnostic tools, and expanded access to newer therapeutic agents. In the absence of such measures, the burden of colistin resistance is likely to persist in hospital settings, including patients requiring intensive care.